Get the Stockscreener App
0.9628
2.27%
-0.0224
Tscan Therapeutics Inc stock is traded at $0.9628, with a volume of 644.65K.
It is down -2.27% in the last 24 hours and down -58.85% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$0.9852
Open:
$0.98
24h Volume:
644.65K
Relative Volume:
1.00
Market Cap:
$50.52M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-0.5379
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
-12.47%
1M Performance:
-58.85%
6M Performance:
-27.06%
1Y Performance:
-75.56%
1-Day Range:
$0.91
$0.9985
1-Week Range:
$0.91
$1.12
52-Week Range:
$0.91
$4.9399
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
0.9628 | 55.91M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Reversal indicators forming on TScan Therapeutics Inc. stockProfit Target & Consistent Profit Alerts - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economyTrade Ideas & Daily Oversold Bounce Ideas - newser.com
Applying chart zones and confluence areas to TScan Therapeutics Inc.2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Is TScan Therapeutics Inc. building a consolidation baseJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
Tscan Therapeutics Inc (TCRX) is looking forward to a strong quarter - Setenews
How TScan Therapeutics Inc. stock performs in high volatility markets2025 Market Outlook & Expert Curated Trade Setups - newser.com
TScan Therapeutics (NASDAQ:TCRX) Cut to Equal Weight at Morgan Stanley - Defense World
Equities Analysts Issue Forecasts for TCRX FY2025 Earnings - Defense World
Best data tools to analyze TScan Therapeutics Inc. stockJuly 2025 Macro Moves & Daily Growth Stock Tips - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fears2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
HC Wainwright Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $7.00 - Defense World
Should you wait for a breakout in TScan Therapeutics Inc.Weekly Risk Summary & Scalable Portfolio Growth Methods - newser.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesWeekly Trade Review & Real-Time Stock Movement Alerts - newser.com
Using data filters to optimize entry into TScan Therapeutics Inc.2025 Earnings Impact & Technical Pattern Recognition Alerts - newser.com
Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight - MarketScreener
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials By Investing.com - Investing.com Canada
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials - Investing.com India
HC Wainwright & Co. Maintains TScan Therapeutics (TCRX) Buy Recommendation - Nasdaq
Is TScan Therapeutics Inc. still worth holding after the dipQuarterly Investment Review & Weekly Breakout Stock Alerts - newser.com
Technical signs of recovery in TScan Therapeutics Inc.Weekly Market Outlook & Accurate Technical Buy Alerts - newser.com
Applying sector rotation models to TScan Therapeutics Inc.Quarterly Portfolio Summary & Low Volatility Stock Recommendations - newser.com
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com
TScan Therapeutics Reports Increased Revenue Amid Rising Losses - TipRanks
Published on: 2025-11-12 17:29:17 - newser.com
Tscan Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com Canada
What technical models suggest about TScan Therapeutics Inc.’s comebackWeekly Investment Report & Community Trade Idea Sharing - newser.com
TScan Therapeutics Draws Analyst Optimism Despite Growing Losses - Finimize
TScan Therapeutics, Inc. Q3 Loss Increases, But Beats Estimates - Nasdaq
TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
TScan Therapeutics Q3 revenue jumps - MarketScreener
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
TScan (NASDAQ: TCRX) secures FDA agreement on TSC-101 pivotal design; runway to 2027 - Stock Titan
Trend analysis for TScan Therapeutics Inc. this weekProduct Launch & Safe Entry Zone Tips - newser.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):